Danaher acquiring Cepheid

Lab equipment and diagnostics company Danaher Corp. (NYSE:DHR) is acquiring molecular diagnostics play Cepheid Inc. (NASDAQ:CPHD) for $53 per share, or about $4 billion including debt and net of cash. The price is a 54% premium to Cepheid's Friday close of $34.42.

Cepheid markets GeneXpert diagnostics for infectious diseases and oncology. The company has 20 approved tests in the U.S. and reported $539 million in revenue in 2015. Danaher expects the deal to close by YE16. ...